AstraZeneca has won approval from the U.S. government to market its new heart drug Brilinta, following a federal probe. The company said the Department of Justice said it is closing its investigation into PLATO, a clinical trial with the drug, and is not planning any further action. It began investigating the PLATO trial, which studied more than 18,000 patients in 43 countries, last October after suspicions were raised that the clinical trial numbers may have been manipulated. In a statement, AstraZeneca CEO Pascal Soriot said, 'We are proud of the important benefit Brilinta offers to patients around the world suffering from acute coronary syndrome.' TheStreet's Brittany Umar reports from New York.